Trisalus Life Sciences Inc (TLSI) Stock Price, Quote & News

Company Profile

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 321 5212

Website: trisaluslifesci.com

Address:

6272 West 91st Avenue, Westminster, United States

PLATINUM_TRADES Feb. 23 at 1:06 PM

$TLSI Let's have another good day! $5.89 Major resistance to break for more 🚨 🚨

0 · Reply

StockScanners Feb. 21 at 6:16 AM

$TLSI keep watch if this holds above 5.50

0 · Reply

StockJelli Feb. 20 at 11:21 PM

Hope everyone is having a Good Friday. Here are the after hours momentum stocks: $RXT $TLSI $RYI $KOS $FNKO

0 · Reply

Stackdoe101 Feb. 20 at 8:10 PM

$TLSI $20 ✨🙃

0 · Reply

topstockalerts Feb. 20 at 7:58 PM

$TLSI Here comes the breakout as volume expands 📈. Buyers are chasing strength. That usually fuels continuation.

0 · Reply

wjmax Feb. 20 at 6:27 PM

$TLSI has the new drug delivery platform that can deliver drug intratumorally and a TLR9 agonist of which Merck also owns some patents. What else does $TLSI need to combine with in order to have efficacy in treating late stage solid tumor? DCVax-Direct from $NWBO!

1 · Reply

HypnoTrader Feb. 20 at 2:09 PM

$TLSI broke out of the base back in November 25. After significant advance, dropped back to same base in anticipation of an offering. Now that the offering is done, if starts breaking out again, maybe worth building a postition. As some trader once said: market always gives you a second chance.

0 · Reply

BillionerOfKing Feb. 19 at 6:05 PM

$TLSI Current Stock Price: $4.52

0 · Reply

IronFade Feb. 18 at 7:21 AM

$TLSI TLSI or unknown micro-cap with minimal public information and likely illiquid.

0 · Reply

AccuRoger Feb. 4 at 2:25 PM

$TLSI presentation tomorrow is announced: 𝐉𝐨𝐢𝐧 𝐔𝐬 𝐚𝐭 𝐒𝐈𝐎 𝟐𝟎𝟐𝟔 Stop by Booth #303 to explore the TriNav® Infusion System Portfolio. Meet our expert team, explore resources, and see a live demonstration! 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐟𝐨𝐫 𝐎𝐮𝐫 𝐋𝐮𝐧𝐜𝐡 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝐓𝐢𝐭𝐥𝐞: “Why Pressure Matters: Optimizing Embolic Delivery using TriNav: How Pressure-Enabled Drug Delivery Works and What Real Cases Reveal” 𝐃𝐚𝐭𝐞: Thursday, Feb 5th 𝐓𝐢𝐦𝐞: 1:00 PM – 1:45 PM

1 · Reply

TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 4 days ago

TriSalus Life Sciences Proposes Public Offering

Feb 9, 2026, 9:00 AM EST - 14 days ago

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

Dec 15, 2025, 5:59 PM EST - 2 months ago

TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript

Dec 4, 2025, 4:01 PM EST - 2 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

Nov 18, 2025, 8:00 AM EST - 3 months ago

TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

Nov 13, 2025, 7:31 PM EST - 3 months ago

TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 3 months ago

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Nov 12, 2025, 4:21 PM EST - 3 months ago

TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript

Nov 11, 2025, 4:05 PM EST - 3 months ago

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

Nov 10, 2025, 8:00 AM EST - 3 months ago

TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 4 months ago

TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

Aug 28, 2025, 8:00 AM EDT - 6 months ago

TriSalus Life Sciences to Participate in Upcoming September Investor Conferences

Aug 12, 2025, 8:53 PM EDT - 6 months ago

TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 6 months ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

Aug 11, 2025, 8:00 AM EDT - 7 months ago

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

Jul 30, 2025, 4:05 PM EDT - 7 months ago

TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:05 PM EDT - 7 months ago

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Jul 24, 2025, 5:58 PM EDT - 7 months ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

Jun 23, 2025, 5:30 PM EDT - 8 months ago

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

Jun 4, 2025, 8:00 AM EDT - 9 months ago

TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

May 30, 2025, 7:00 AM EDT - 9 months ago

TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

May 15, 2025, 6:45 PM EDT - 10 months ago

TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 7:00 AM EDT - 10 months ago

TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

May 12, 2025, 4:30 PM EDT - 10 months ago

TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

Apr 30, 2025, 8:00 AM EDT - 10 months ago

TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

Mar 30, 2025, 8:02 AM EDT - 11 months ago

TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks

Mar 27, 2025, 2:02 PM EDT - 11 months ago

TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:30 AM EDT - 11 months ago

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 8:00 AM EDT - 11 months ago

TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

Mar 6, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

Feb 3, 2025, 4:05 PM EST - 1 year ago

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Feb 3, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed

Jan 23, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

Jan 9, 2025, 8:00 AM EST - 1 year ago

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

Dec 24, 2024, 11:29 AM EST - 1 year ago

TriSalus Life Sciences: Continuing To Maintain Optimism As Costs Are Cut

Nov 14, 2024, 10:22 AM EST - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:00 AM EST - 1 year ago

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

Nov 7, 2024, 7:00 AM EST - 1 year ago

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

Oct 31, 2024, 8:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Oct 14, 2024, 4:05 PM EDT - 1 year ago

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 26, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

Sep 23, 2024, 7:00 AM EDT - 1 year ago

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Aug 15, 2024, 2:33 PM EDT - 1 year ago

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:00 AM EDT - 1 year ago

TriSalus Reports Q2 2024 Financial Results and Business Update

Aug 1, 2024, 7:00 AM EDT - 1 year ago

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

Jul 1, 2024, 4:00 PM EDT - 1 year ago

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

Jun 26, 2024, 5:45 PM EDT - 1 year ago

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

PLATINUM_TRADES Feb. 23 at 1:06 PM

$TLSI Let's have another good day! $5.89 Major resistance to break for more 🚨 🚨

0 · Reply

StockScanners Feb. 21 at 6:16 AM

$TLSI keep watch if this holds above 5.50

0 · Reply

StockJelli Feb. 20 at 11:21 PM

Hope everyone is having a Good Friday. Here are the after hours momentum stocks: $RXT $TLSI $RYI $KOS $FNKO

0 · Reply

Stackdoe101 Feb. 20 at 8:10 PM

$TLSI $20 ✨🙃

0 · Reply

topstockalerts Feb. 20 at 7:58 PM

$TLSI Here comes the breakout as volume expands 📈. Buyers are chasing strength. That usually fuels continuation.

0 · Reply

wjmax Feb. 20 at 6:27 PM

1 · Reply

HypnoTrader Feb. 20 at 2:09 PM

0 · Reply

BillionerOfKing Feb. 19 at 6:05 PM

$TLSI Current Stock Price: $4.52

0 · Reply

IronFade Feb. 18 at 7:21 AM

$TLSI TLSI or unknown micro-cap with minimal public information and likely illiquid.

0 · Reply

AccuRoger Feb. 4 at 2:25 PM

1 · Reply

SuperGreenToday Jan. 23 at 6:12 AM

$TLSI

0 · Reply

BillionerOfKing Jan. 22 at 12:53 PM

$TLSI Current Stock Price: $5.52

0 · Reply

DARKP00L Jan. 12 at 12:36 PM

$TLSI 07:23 on Jan. 12 2026 TriSalus Posts $13.2M Q4 Revenue Vs $12.68M Est, $45.2M for 2025 Vs $44.62M Est, Guides $60M–$62M Sales in 2026 Vs $63.77M Est #tradeideas

0 · Reply

AccuRoger Jan. 8 at 2:25 PM

$TLSI This is mouse data only using Nelitolimod (SD-101). It is reported by a group of Chinese researchers. The mechanism of action is interesting. Quote Here, we developed a novel whole-cell vaccine, termed MDLSD, by combining mitoxantrone (MTX)-induced ICD with the TLR9 agonist SD-101. In murine Lewis lung carcinoma (LLC) models, MDLSD demonstrated superior prophylactic and therapeutic efficacy. Mechanistically, MTX-induced dying tumor cells (MDL) promoted dendritic cell (DC) phagocytosis, while the addition of SD-101 was essential for driving complete DC maturation through potent upregulation of CD80. https://www.sciencedirect.com/science/article/abs/pii/S1567576925021411

0 · Reply

garygb Jan. 3 at 6:36 PM

$TLSI Bought this one too soon. Still holding

0 · Reply

garygb Jan. 2 at 5:36 PM

$TLSI oversold cancer drug.

0 · Reply

wjmax Dec. 31 at 4:22 PM

$NWBO Both $INDP and $TLSI which in my opinion is positively related to DCVax technology are going up too. It could be coincidental.

0 · Reply

InsightIsle Dec. 25 at 5:31 PM

$TLSI What matters next is the company’s ability to build a predictable delivery rhythm. Structural initiatives require practical follow‑through to gain credibility. Momentum becomes sustainable only with dependable execution. The thesis improves only as operational proof accumulates.

0 · Reply

DebtFreeDave Dec. 24 at 12:39 PM

$TLSI Sentiment could pivot sharply depending on how resource allocation supports scalability without eroding optionality. Execution slippage remains the dominant downside risk.

0 · Reply

DARKP00L Dec. 17 at 8:28 PM

$TLSI 15:08 on Dec. 17 2025 Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12 #tradeideas

0 · Reply

JarvisFlow Dec. 17 at 8:08 PM

Canaccord Genuity has updated their rating for TriSalus Life Sciences ( $TLSI ) to Buy with a price target of 12.

0 · Reply

SuperGreenToday Dec. 15 at 8:16 PM

$TLSI

0 · Reply

Market Cap	272.30M
Revenue (ttm)	29.43M
Net Income (ttm)	-30.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.11%
Debt to Equity Ratio	-1.23

Volume	202,300
Avg Vol	180,474
Day's Range	N/A - N/A
Shares Out	49.96M
Stochastic %K	96%
Beta	0.42
Analysts	Strong Sell
Price Target	$11.50